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Abstract
This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone
(DEX) to the ocular posterior segment using a Laponite (LAP) carrier—DEX/LAP 1:10 w w−1
formulation; 10 mg ml−1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and
suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a
DEX solution (1 mg ml−1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15
suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks
1–4–12–24 post-administration. Three eyes per sample time point were used to quantify DEX
concentration using high-performance liquid chromatography-mass spectrometry. The ocular
tissues’ pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were
studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX
levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after
administration. The vitreous area under the curve was significantly greater after both DEX/LAP
deliveries (IV: 205 968.47; SC: 11 442.22 ng g−1 d−1) than after IV administration of the DEX
solution (317.17 ng g−1 d−1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels
up to week 24 (466.32± 311.15 ng g−1). With SC delivery, DEX levels were detectable in the
choroid-retina unit (12.04± 20.85 ng g−1) and sclera (25.46± 44.09 ng g−1) up to week 24. This
study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP
formulation. The LAP increased the intraocular retention time of DEX when compared with
conventional solutions. DEX/LAP could be considered a biocompatible and useful
sustained-release formulation for treating posterior-pole eye diseases.
1. Introduction
Glucocorticosteroids (GCs) have been widely used in
clinical practice to treat posterior-segment eye dis-
eases such as non-infectious posterior uveitis, dia-
betic retinopathy, retinal vein occlusion or age-related
macular degeneration with macular oedema [1–5].
However, posterior segment processes are especially
difficult to treat because of poor tissue permeability,
anatomical and physiological barriers in the eye and
low drug bioavailability in the target tissue [6–9]. The
routes typically used [10] to administer GCs in oph-
thalmology are, in many cases, insufficient to deliver
and maintain therapeutic drug levels in the posterior
segment [11]. High and frequent doses by topical
and systemic administration or by periocular and
intravitreal (IV) injection are required, causing sig-
nificant harmful side effects [12, 13] and heightened
© 2020 The Author(s). Published by IOP Publishing Ltd
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risk of severe ocular complications [14, 15]. To over-
come these limitations, alternative drug delivery sys-
tems and sustained-release formulations are being
developed [16, 17].
IV administration of GCs by injection or by
implantation of surgical devices have a powerful
therapeutic effect on neuroretinal tissues by achiev-
ing high local drug concentrations in the vitreous
humour near their site of action [3, 18]. This route
acts as a reservoir and minimizes the systemic side
effects. However, as it is an invasive route it could
lead to local complications, such as retinal tox-
icity or detachment, lens injury, intraocular infec-
tions or haemorrhages, and elevated intraocular pres-
sure (IOP) [14, 19, 20]. Periocular routes offer an
alternative means of delivery to the posterior seg-
ment of the eye due to their ability to bypass the
conjunctiva–cornea barrier, thereby enabling dir-
ect transscleral delivery [21]. Among the different
forms of periocular administration, suprachoroidal
(SC) injection is an emerging technique considered
to be more effective than the subconjunctival or
subtenon routes and to be safer than IV injection
[22–25]. The suprachoroidal space (SCS) is a poten-
tial space located between the sclera and choroid
that can expand to accommodate drug formula-
tions [24, 26–28]. It delivers higher drug concen-
trations in the area spanning the retina–retinal pig-
ment epithelium–choroidal unit and the posterior
pole, and minimizes the presence of the drug in the
anterior structures of the eye [23–25, 29–33]. How-
ever, drug efficacy varies among formulations due to
the high rate of clearance in the SCS and to the differ-
ing physico-chemical properties and size or molecu-
lar radius of the drug, aswell as depending onwhether
the formulation is viscous or particulate, among other
aspects [22, 23, 26, 27, 29, 32, 34, 35]. SC administra-
tion represents a promising alternative route for treat-
ing posterior-segment eye diseases and has become a
focus of drug delivery research [22, 36, 37].
Several GCs such as triamcinolone acetonide
(TA), dexamethasone (DEX) and fluocinolone acet-
onide (FA), with which to treat posterior eye dis-
ease are now available [38]. TA is a potent selective
GC agonist with low water solubility (21 µg ml−1),
which confers a sustained release in aqueous media
[3, 23]. TA showed efficacy for diabetic macular
oedema, retinal vein occlusion and non-infectious
posterior uveitis in human and animal studies after
IV or SC administration [25, 28, 39–42]. In con-
trast, DEX is more potent and has a lower risk
of inducing ocular hypertension and cataracts after
IV administration than TA [3], but it has a short
half-life (3.5 h) [19] and higher water solubility
(100 µg ml−1), which reduces its clinical application
when used in conventional formulations. Therefore,
sustained-delivery systems (implants) are necessary
to maintain long-lasting therapeutic effects and avoid
re-injections. IV implants [43] require placement
in the operating room, injection using larger gauge
needles or even surgical extraction devices in the case
of non-biodegradables (such as Retisert® and Ilu-
vien® made of FA), and therefore conferring greater
risk. Biodegradable IV DEX implants (Ozurdex®)
are widely used in clinical care and their efficacy
has been proved. However, IOP increases and catar-
acts are relatively frequent due to the passing of
DEX to the anterior eye structures [44]. To reduce
those side effects, SC administration may be more
appropriate.
Nowadays, to create anti-inflammatory [45–49]
treatments a wide variety of polymeric nanocarri-
ers in the form of dendrimers, micelles, nanocap-
sules and vesicles, liposomes or nanoparticles and
nanogels are being investigated [50]. These formu-
lations are made of smart materials, which control
drug release in response to exogenous or endogen-
ous stimulations such as pH fluctuation, temperature
or isquemic conditions. Gold nanoparticles loaded
with DEX released the drug and induced apoptosis
on a DEX sensitive lymphoma cell line [48]. A DEX-
loaded lipid nanoemulsion with specific binding to
endothelial cells via the P-selectin target reduced vas-
cular inflammation in vitro and in vivo, after intern-
alizing into the endothelial cell, reducing proinflam-
matory gene expression, and preventing monocyte
adhesion and migration [47]. A combination of DEX
and cholesteryl butyrate in solid-lipid nanoparticles
relieved colon inflammation at doses lower than the
required for each single drug [46]. And microplates
made of poly(lactic-co-glycolic acid sustained release
DEX for up to 60 d and decreased expression of the
inflammatory cytokines IL-1β, IL-6 and TNF-α [49].
There is currently demand for biocompatible and
biodegradable sustained-release formulations con-
taining GCs for ocular administration by minimally
invasive (IV or SC) injection in clinical practice [28,
51, 52]. DEX loaded oligo-cationic liposomes, by IV
administration slowly released DEX for more than
20 d. And a polysaccharide-drug conjugate composed
of hydrazine-DEX showed a very slow diffusivity and
prolonged drug release in vitreous humour [49]. To
the authors’ knowledge, only one study featuring
implantation of DEX in the SCS has been conduc-
ted. This paper demonstrated sustained DEX delivery
from a polyurethane implant for 42 d and decreased
inflammatory signs in uveitic rats [53].
Synthetic and natural clays have received great
attention as drug delivery modulators in biomedical
applications due to their ability to control or vector-
ize the release of drugs and increase bioavailability
[54]. Laponite (LAP) is a synthetic colloidal layered
silicate (Na0.7[(Si8Mg5.5Li0.3)O20(OH)4]0.7) used
in various drug delivery applications in nanomedi-
cine to treat skin, bones and cancer [55, 56]. Admin-
istration of LAP in rabbit eyes has also been shown
to be safe and biocompatible, with long-lasting
intraocular residence after SC and IV injection [57].
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LAP has a high total surface area and offers cation
exchange capacity, interchanging sodium counter
ions in aqueous saline solution [58, 59], becoming
a transparent thixotropic gel that allows adminis-
tration by injection and providing good dispersibil-
ity and a stable structure [60]. In previous in vitro
studies [61], we first demonstrated that DEX, des-
pite being a neutral molecule, is retained on LAP
due to weak non-ionic interactions (mainly hydro-
gen bonds). These findings were later corroborated by
other authors [62]. DEX was also shown to be encap-
sulated in and uniformly distributed on the surface of
LAP nanoplatelets, to possess pH-dependent proper-
ties and to have good in vitro cytocompatibility with
MG63 cells [63]. The DEX/LAP formulation showed
an initial burst release of DEX (of around 40% of the
initial dose loaded on LAP, which is consistent with
other drugs [64]) in saline or hyaluronate solutions,
with subsequent progressive, sustained drug delivery
[61, 62].
In this manuscript we describe the first in vivo
application of the DEX/LAP formulation for sus-
tained release of DEX. Specifically, it has been used
in the ocular posterior segment and its ocular phar-
macokinetics has been characterized over 6 months




2.1.1. Chemical and reagents
DEX was obtained from Sigma-Aldrich (Mad-
rid, Spain). Laponite®-RD (LAP) (surface dens-
ity 370 m2 g−1, bulk density 1000 kg m−3, chem-
ical composition: SiO2 59.5%, MgO 27.5%, Li2O
0.8%, Na2O 2.8%) was obtained from BYK Addit-
ives (Widnes, Cheshire, UK). The balanced 0.9% salt
solution (9 mg ml−1 NaCl) (BSS) was obtained from
Fresenius Kabi (Barcelona, Spain). The HPLC-grade
ethanol and acetonitrile were obtained from Scharlab
(Barcelona, Spain).
2.1.2. Preparation and characterization of the
DEX/LAP formulation
The optimal loading of DEX on LAP was determined
by our group in previous work based on the nature
of the drug–clay interaction, where DEX was incor-
porated on the surface of the clay nanoplatelets and
the in vitro behaviour of the medium in relation to
the release of the drug was studied [61]. DEX/LAP
was prepared by adding LAP (100 mg) to a solution
of DEX in ethanol (10 mg/10 ml), stirring at r.t. and
solvent evaporation under vacuum to get a good dis-
persion of DEX on the surface. TheDEX/LAP powder
was stored in tightly capped single-use vials that were
gamma-ray sterilized.
Immediately before injection, the DEX/LAP
powder was suspended in BSS (10 mg ml−1) and
gently vortexed for 10 min to yield a transparent col-
loidal dispersion.
2.2. In vivo study design
2.2.1. Ethics statement
All experiments were carried out using female
New Zealand albino rabbits (obtained from the
Animal Experimentation Service of the University
of Zaragoza). Animal handling was in accordance
with the Spanish Policy for Animal Protection (RD
1201/05), which meets European Council Direct-
ive 86/609/EEC. Animal care and practices complied
with the ARVO Statement for the Use of Animals
in Experimental Procedures and Other Scientific
Purposes. All procedures were performed accord-
ing to Project Licence PI12/02285 approved by the
in-house Ethics Committee for Animal Experiments
at the University of Zaragoza (Spain). The animals
were singly housed in metabolic standard cages, in a
light-controlled room (12 h/12 h dark/light cycle) at
20 ± 2 ◦C with a relative humidity of 40–70%. Diet
and water were available ad libitum and thorough
clinical examination was performed daily.
2.2.2. In vivo administration: injection procedure
Thirty animals weighing 2.5–4.0 kg (3.1 ± 0.4 kg)
were included in the study and randomly divided into
two groups. Fifteen animals received suprachoroidal
administration (SC group) and the other 15 animals
received an IV injection (IV group) of the DEX/LAP
formulation (10 mg ml−1, 1:10 w w−1). Only one eye
(right eye) of each animal was treated. The fellow eye
(left eye) remained untreated and served as the com-
parative control. Data from 18 animals injected with
DEX IV were also served as comparison [65].
All the injections were performed under gen-
eral anaesthetic and aseptic conditions. For IV
injection, the animals were anaesthetized by
intramuscularly injecting ketamine hydrochloride
(25 mg kg−1) (Ketolar 50®, Pfizer, Madrid, Spain)
and medetomidine (0.5 mg kg−1) (Domtor®, Esteve,
Madrid, Spain). As SC administration was a longer
procedure, a general inhalation anaesthetic contain-
ing 2.5% sevoflurane (Sevorane®, Abbott Labor-
atories, Madrid, Spain) was administered in oxy-
gen by mask and vital signs were monitored. A
topical anaesthetic containing tetracaine chlorhy-
drate (1 mg ml−1) and oxybuprocaine chlorhydrate
(4 mg ml−1) in the form of ophthalmic drops (Colir-
cusí Anestésico Doble®, Alcon Cusí SA, Barcelona,
Spain) was administered, and povidone-iodine solu-
tion (5%) was applied for ocular surface antisepsis
before and after the injection.
The same ophthalmologist performed all the
eye injections under the direct view of a surgical
microscope (Zeiss Opmi 6 c/Osmi 99 Microscope,
Carl Zeiss Meditec Inc. California, USA). Following
administration, the animals were allowed to recover
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from the anaesthetic, and the health state of the eye
surface was monitored.
2.2.3. Determination of injection volumes
Volumes of 100 µl and 50 µl of DEX/LAP suspen-
sion were used for IV and SC administration, respect-
ively. The DEX dose used was 0.1 mg in 100 µl for
IV injection and 0.05 mg in 50 µl for SC injection.
The volumes of formulation determined for IV and
SC injection were the highest volumes that could be
safely administered by either route without risk of
leaking, elevating IOP or inducing choroidal haem-
orrhage [23, 57, 66].
2.2.4. SC injection
SC administration was carried out in the superior
nasal quadrant of the eye by cannulation of the SCS
[41]. The sclera was exposed by performing a con-
junctival peritomy with a radial cut parallel to the
superior rectus muscle. A deep intrascleral incision
was made about 9 mm past the limbus, near the
2 o’clock meridian. A blunt spatula was used to dis-
sect the sclera and enter the SCS, making a tiny
pocket intended to serve as a reservoir. Direct admin-
istration of 50 µl of DEX/LAP suspension was per-
formed by injection using a 25 gauge irrigating can-
nula (angled 35◦, 7.0 mm from bend to tip, 19.0 mm
overall length excluding hub) attached to a 1 ml
syringe. The port of the pocket was occluded with
surgical microsponges and maintained for 1 min to
prevent as much leaking at the site of injection as
possible, however a minimum leaking occurred and
unfortunately the lost volume could not be quanti-
fied. Finally, the conjunctiva was repaired with an 8-0
suture.
2.2.5. IV injection
IV injectionwas performed using a 25 gauge needle in
the superior temporal quadrant, about 3–5 mm pos-
terior to the limbus and towards the centre of the vit-
reous cavity. Paracentesis had been performed before-
hand in the anterior chamber using a 30 gauge hollow
needle to remove aqueous humour so as to avoid elev-
ating IOP. After the injection, the absence of reflux
was verified in all cases by gentle compression of the
injection point for 30 s with a cotton swab.
2.2.6. Clinical safety after ocular administration of the
DEX/LAP formulation
After ocular administration of the DEX/LAP formu-
lation in both groups (SC and IV), the eyes weremon-
itored using ocular tonometry, slit-lamp examination
and indirect ophthalmoscopy at day 1 and at weeks 1,
4, 12 and 24 before euthanasia, as described in our
previous report [57].
2.3. Pharmacokinetic (PK) study
To determine eye-tissue drug concentrations and for
subsequent ocular PK studies, three animals from
each sampling time point (at day 1 and at weeks 1,
4, 12 and 24) were used. The animals were humanely
euthanized using a rapid intravenous injection of
sodium pentobarbital (30 mg kg−1) through the ear
vein. Immediately after euthanasia, the eyes were
enucleated and the globes were snap-frozen (−40 ◦C)
for posterior dissection of the lens, vitreous, choroid-
retina unit and sclera. Each part was mixed with acet-
onitrile (2ml), vortexed for 1min, sonicated for 5min
to ensure thorough mixing, and finally centrifuged at
3000 rpm for 5 min. The supernatant was collected
and evaporated under vacuum.
2.3.1. Analytical method
DEX concentrations in ocular tissue were determined
using a simple and easily accessible method—high-
performance liquid chromatography–mass spec-
trometry (HPLC-MS)—in a Waters 2695 system
equipped with a Phenomenex Kinetex C18 column
(75 mm × 4.6 mm × 2.6 µm) coupled to a Waters
ZQ4000MS detector. A 35:65 mixture of acetoni-
trile and formic/formate buffer (2 mM ammonium
formate buffer, adjusted to pH 3.5 with formic
acid and doped with sodium formate 0.2 mM) was
used as mobile phase. The dried samples obtained
as described above were then dissolved in 200 µl
of acetonitrile containing 6-α-methylprednisolone
(20 ppm, internal standard), filtered through a
0.22 µm PTFE syringe filter and analysed. Analyt-
ical method validation was carried out according to
ICH guidelines. Linearity was assessed by seven-point
calibration curves in triplicate. The curves were con-
structed over a range between 50 and 100 000 ng g−1.
The limit of detection (LOD, 10 ng g−1) and the
lower limit of quantification (LLOQ, 45 ng g−1) were
determined by the method based on the standard
deviation of the slope and response. Full details for
this method have been published elsewhere [65].
2.3.2. PK analysis
DEX concentrations were determined in the dif-
ferent tissues of both injected and control eyes to
perform PK analysis. PK data were analysed for
best fit and were consequently modelled accord-
ing to a non-compartmental model using Microsoft
Excel’s PK Solver Add-in (Albuquerque, NM,USA) in
which equations describing concentration as a func-
tion of time are used. The following PK paramet-
ers were obtained: peak concentration (Cmax), time
to peak concentration (Tmax), elimination half-life
(T1/2), elimination rate constant (Ke) as derived from
the elimination half-life of the drug (Ke = 0.693/T1/2),
drug clearance (Cl), distribution volume (Vss) and the
area under the concentration–time curve (AUC0-∞).
To describe the concentration–time of DEX after
administration, the following equation was used:
C_tissue = C_0∧∗e∧(−K_e t), where C is the tis-
sue concentration and C0 is the concentration at
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time T0. The area under the concentration–time
curve (AUC0−∞) was estimated using the linear–
trapezoidal method taking the experimental tissue
concentrations over 24 weeks, in which the area from
the last concentration point (Tlast = day 168) to infin-
ity (∞) was calculated as Clast/Ke.
Finally, vitreous availability of DEX after LAP/-
DEX administration was calculated and indicates the
fraction of the administered drug that is absorbed and
reaches the vitreous humour (F = AUC0−∞∗Cl/D).
The relative vitreous availability of DEX after SC
injection was also calculated with respect to the IV
route (Fsc/iv = AUCsc∗Div/AUCiv∗Dsc).
2.4. Statistical analysis
Statistical analyses were performed using SPSS ver-
sion 21.0 (SPSS Inc. Chicago, IL). Data on DEX
concentrations were expressed as mean ± standard
deviation. The Shapiro–Wilk test was used to determ-
ine goodness of fit to the continuous variables’ nor-
mal distribution. Student’s t-test was used to com-
pare PKparameters between the groups. Other results
were assessed using descriptive measures, and Pear-
son’s Chi-Square test was used to compare categorical
data. Statistical significance was accepted at a level of
p < 0.005.
3. Results
3.1. Clinical safety after ocular administration of
the DEX/LAP formulation
The clinical ophthalmological signs in eyes after SC
and IV administration of the DEX/LAP formulation
are detailed in table 1.
Both SC and IV DEX/LAP injection were well tol-
erated. No case of infection, inflammation or ocu-
lar hypertension was detected (IOP ranged from 7
to 16 mmHg in both routes of administration under
study). Variable grades of conjunctival hyperaemia
and swelling were observed in both groups, although
these were more intense in SC delivery and included
haemorrhages located around the administration site
up to week 1. Variable corneal epithelial defects were
also observed, probably due to the surgical proced-
ure. The IV group showed a higher rate of early catar-
act formation, in the form of focal opacity located
in the posterior lens capsule, which did not interfere
with the ophthalmoscope examination. This was also
attributed to technical issues associated with rabbits’
large lens. Using ophthalmoscopy, the DEX/LAP sus-
pension could be observed in the vitreous as a trans-
parent floater from 24 h up to 24 weeks after adminis-
tration, and without any signs of inflammation of the
retina or optic nerve.
3.2. Concentrations of DEX in posterior-segment
eye tissue
Figure 1 shows the concentration–time curves in the
ocular tissues (lens, vitreous, choroid-retina unit and
sclera) over the course of the study following SC
administration of DEX/LAP suspension. Concentra-
tion is expressed in nanograms of DEX per gram
of the specific ocular tissue. The highest intraocular
DEX levels after SC administration were observed in
the vitreous humour (460.38 ± 93.79 ng g−1) fol-
lowed by the choroid-retina (275.54± 164.85 ng g−1)
at 1 week. Vitreous DEX levels experienced the most
abrupt decrease (under the lowest limit of detection
(LLD: 10 ng g−1) at 12 weeks), contrasting with the
other tissues, which experienced a gentler decrease.
DEX levels in the sclera and choroid-retina unit plat-
eaued fromweeks 12 to 24 andmaintained detectable
concentrations in the sclera (25.46 ± 44.09 ng g−1)
and choroid-retina (12.04 ± 20.85 ng g−1) up to the
end of the study (week 24). These values were lower
than expected, probably due to leaking in the admin-
istration procedure.
After IV administration, DEX was only detec-
ted in the vitreous humour. Levels in the other
ocular tissues (lens, choroid-retina and sclera)
were below the lowest limit of detection for the
analytical method used. Peak DEX concentration
(2258.00 ± 1610.32 ng g−1) was observed on
day 1 and then drastically decreased, plateauing
(626.42 ± 251.31 to 466.32 ± 311.15 ng g−1) from
weeks 1 to 24 after administration (see figure 2).
DEX concentrations in the vitreous humour
after SC and IV administration were compared
(figure 2). Direct injection of DEX/LAP suspension
into the vitreous humour showed 7 times higher
DEX concentration at day 1—although the levels
were roughly equal at week 1 (626.42 ± 251.31
vs 460.38 ± 93.79 ng g−1)—and concentration
remained higher at week 24 (466.32 ± 311.15 ng g−1
vs non-detectable levels) than when DEX/LAP sus-
pension was administered suprachoroidally. DEX
levels were not detectable in contralateral eyes (in
the vitreous humour or choroid-retina unit) after
both SC and IV administration of the DEX/LAP
formulation.
3.3. Ocular tissue pharmacokinetics
The experimental levels of DEX in ocular tissue
over time after both SC and IV administration of
DEX/LAPmay be explained by a non-compartmental
model. In the case of the SC route, there were
not enough experimental points for compartmental
modelling. Meanwhile, the IV route showed a good
correlation between observed and predicted concen-
trations with this model (R2 = 0.9897).
Following the SC route, the maximum concen-
trations (Cmax) were found in the vitreous humour
(460.38 ng g−1), sclera (283.53 ng g−1) and choroid-
retina unit (275.54 ng g−1). Times of maximum
concentration (Tmax) were achieved at day 7 after
administration, with the exception of the sclera
(day 1). The scleral tissue showed the highest area
under the concentration–time curve value (AUC:
5
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Figure 1. DEX concentrations in posterior segment tissues (lens, vitreous, choroid-retina unit and sclera) after SC administration
of DEX/LAP (1:10 w w−1) suspension (10 mg ml−1). Data expressed as mean± sd. n= 3 animals per sampling time point.
Abbreviations: ng: nanograms; g: grams; w: week.
Figure 2. DEX concentrations in the vitreous humour after IV and SC administration of DEX/LAP (1:10 w w−1) suspension
(10 mg ml−1). Data expressed as mean± sd. n= 3 animals per sampling time point.
12 399.70 ng g−1 d−1) after SC administration.
Although the vitreous humour was the intraocular
tissue that exhibited the lowest distribution volume
(V ss: 35.80 g), it nevertheless showed a large AUC
(11 442.22 ng g−1 d−1). The longest elimination half-
life (T1/2) was found in the sclera (48.05 d), fol-
lowed by the choroid-retina unit (36.37 d). There
were similar drug clearance (Cl) values in all ocular
tissue: 4.724 g d−1 in the lens, 4.369 g d−1 in the
vitreous, 5.118 g d−1 in the choroid-retina unit, and
4.032 g d−1 in the sclera. Table 2 shows the PK para-
meters of the DEX in the rabbits’ ocular tissues after
SC administration of DEX/LAP suspension.
PK parameters of the DEX in the rabbits’ vitreous
humour after IV administration of DEX/LAP suspen-
sion are shown in table 3. It compares the vitreous
PK parameters of DEX versus SC and IV administra-
tion of DEX/LAP, and versus IV injection of DEX in
solution (1 mg ml−1) (data taken from our previous
study [65]).
Following the IV route, the maximum concen-
tration of DEX achieved in the vitreous humour
after administration of DEX/LAP suspension was
higher than that achieved with DEX solution (Cmax:
2258.00 ng g−1 vs 112.27 ng g−1). Even when
the DEX/LAP suspension was administered suprac-
horoidally, vitreous levels were higher than after dir-
ect IV injection of DEX solution (460.38 ng g−1 vs
112.27 ng g−1). The vitreous AUC was significantly
larger (p = 0.036) after IV and SC administration of
DEX/LAP suspension than following IV injection of
DEX solution (205 968.47 and 11 442.22 ng g−1 d−1,
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Table 2. Ocular tissue PK parameters after SC administration of DEX/LAP suspension.
PK parameters Units Lens Vitreous humour Choroid-retina unit Sclera
Ke d
−1 0.031 0.122 0.019 0.014
T1/2
a d 22.65 5.68 36.37 48.05
V ss g 154.38 35.80 268.58 279.51
Cl g d−1 4.724 4.369 5.118 4.032
AUC0-∞ ng g
−1 d−1 10 584.36 11 442.22 9768.63 12 399.70
Cmax ng g
−1 263.34 460.38 275.54 283.53
Tmax d 7 7 7 1
aThe T1/2 value was determined by calculating the lambda Z parameter (0.05 d-1).
Table 3. Vitreous PK comparison. Vitreous humour PK parameters following 50 µl SC and 100 µl IV administration of DEX/LAP
(1:10 w w−1) suspension (10 mg ml−1) compared to IV injection of DEX in solution (1 mg ml−1) [65]. A non-compartmental model
was achievable for vitreous levels in the DEX/LAP administration groups—IV and SC. The monocompartmental model was a fit for
vitreous levels in IV delivery of DEX in solution.
PK parameters Units
SC DEX-LAP
(1:10 w w−1) (10 mg ml−1)
IV DEX-LAP
(1:10 w w−1) (10 mg ml−1)
IV DEX solution
[65] (1 mg ml−1)
Ke d
−1 0.122 0.005∗ 5.48
T1/2
a d 5.68 134.75 0.13
V ss g 35.80 97.57
∗ 57.55
Cl g d−1 4.369 0.486∗ 315.29
AUC0-∞ ng g
−1 d−1 11 442.22 205 968.47 317.17
Cmax ng g
−1 460.38 2258.00 112.27
Tmax d 7 1 0.5
F % 99.98 100.10 100.00
aThe T1/2 value was determined by calculating the lambda Z parameter (0.05 d−1).
∗Statistical difference at p < 0.05 compared with that of SC administration, calculated using Student’s t-test.
respectively, vs 317.17 ng g−1 d−1). SC administra-
tion of DEX/LAP suspension showed the lowest dis-
tribution volume (35.80 g), (p= 0.022).
DEX/LAP suspension, for both the SC and IV
routes, showed a vitreous DEX elimination rate that
was significantly lower (p = 0.023) than that found
after IV administration of the DEX solution, with a
clearance of 4.37, 0.49 vs 315.29 g day−1, respectively.
The half-life of DEX in the vitreous was extended
from 0.13 d (IV DEX solution) to 5.68 d and 134.75 d
(SC and IV DEX/LAP suspension, respectively) when
the new LAP formulation was used.
Figure 3 shows the differences in DEX
concentration–time profiles in the vitreous humour
between the two IV formulations (DEX/LAP sus-
pension and DEX solution) in order to observe the
effect of the long-lasting release of DEX from the
LAP carrier. In the vitreous humour, DEX levels
remained detectable for up to 168 d after injection of
the DEX/LAP formulation (figure 3(A)). In contrast,
levels of DEX rapidly decreased within 24 h of admin-
istration of the solution (figure 3(B)).
4. Discussion
Treatment of chronic posterior segment patholo-
gies with GCs requires sustained-release systems that
maintain therapeutic levels of the drug near the site
of action for long periods of time and with the
least number of re-injections, since repeated injection
has been shown to worsen patient compliance and
increase the risk of possible severe ocular complica-
tions [67].
The vitreous is considered a natural ocular drug
reservoir that extends therapeutic application near its
site of action (the choroid-retina unit) [68]. However,
part of the IV-administered dose is ‘lost’ through the
anterior or posterior pathways, producing undesir-
able effects such as increased IOP or cataracts [69,
70] in addition to being greatly diluted due to the
high water content of the vitreous humour [35] and
having to pass through the retinal pigment epithe-
lium (RPE) barrier, all of which reduces the bioavail-
ability of the drug in the choroid-retina unit. SC
administration maintains higher drug levels in the
choroid-retina unit compared to IV delivery [31].
SC administration has the handicap of rapid clear-
ance, as the choroid has the greatest vascular flow
per unit of weight (62 ml h−1 in rabbits [71] and
1200 ml/100 g min−1 in humans [31]) and the chori-
ocapillaris is fenestrated, which rapidly decreases
the bioavailability of the drug administered in
the SCS.
In order to overcome these limitations, research
has been conducted in recent years into nanoparticle
systems [72] capable of sustained release of drugs,
thereby making it possible both to decrease the
dose administered and to deliver them locally at
the target site—the choroidal retinal tissue—in the
posterior segment [25] over prolonged periods of
time. Meanwhile, the high hydrosolubility of DEX
means that in order to administer it intravitreally
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Figure 3. DEX concentrations in the vitreous humour after IV administration of DEX/LAP suspension (A) and DEX solution (B).
Data expressed as mean± sd. n= 3 animals per sampling time point.
or suprachoroidally it is necessary to develop sys-
tems that allow sustained long-term release of
the drug.
In previous papers, our group created and char-
acterized, in vitro, a new DEX formulation using
a LAP matrix as the base (DEX/LAP formulation).
DEX/LAP showed an initial burst release of less than
40% followed by sustained release of DEX from the
carrier LAP for up to 24 weeks [61]. It also demon-
strated the ocular feasibility and safety of IV and SC
administration of LAP [57]. This study evaluates the
ocular safety and PK profile of the newDEX/LAP for-
mulation when administered in rabbit eyes after hav-
ing demonstrated the suitability of this animal model
in the form of a good pharmacokinetic correlation
between the rabbits’ vitreous humour and that of
humans [71].
4.1. Analysis of IV administration
Currently, GCs are available that can be administered
intravitreally either in suspension (TA) or in biode-
gradable (DEX) or non-biodegradable (FA) implants
[70]. After IV administration, their ocular kinetics
show an initial burst peak in the vitreous and then
progressively and variably decrease until the levels sta-
bilize, after which they fall further until they become
non-detectable. IV TA (Kenalog®), DEX (Ozurdex®,
Cortiject®, Posurdex®) and FA (Retisert®, Illuvien®)
implants have different delivery mechanisms that
contribute to the differing durations of their thera-
peutic effect (approximately 2 months, 4 months,
and years, respectively). Studies in rabbits using IV
TA showed high vitreous levels on day 1 followed
by an exponential decrease up to week 4 and then
a steady decline over the following months, with
a Cmax greater than 10 000 ng g−1. However, IV
FA implants (Retisert® or Illuvien®) show low and
constant vitreous levels from 2 h up to more than
1 year, with a Cmax of 1–20 ng g−1. It has been
hypothesized that GCs with a near zero-order burst
maintain their efficacy for longer because, in con-
trast, a very high initial dose may make the cells
dependent on high doses to maintain the same effect
[70]. Furthermore, studies comparing dose efficacy
showed that low doses (SC administration) can be
just as effective as high IV doses in controlling acute
inflammation [22]. Increasing the dose of steroids
released does not necessarily result in a correspond-
ing increase in efficacy [70]. We were unable to cor-
roborate these findings in our study, however, as our
animals were healthy. RegardingDEX (the GC chosen
in this study), various trials have been conducted
using sustained-release systems like Cortiject® (for
DME), Posurdex (for DME and posterior uveitis), as
well as the FDA-approved and commercially available
surgically placed biodegradable PLGA (poly-lactic-
glycolic acid) IV implant Ozurdex® that it is widely
used in clinical practice. Ozurdex® maintains in vitro
release of DEX for 6 months. Chang-Lin et al [73]
demonstrated in male monkeys that vitreous DEX
peaked at month 2. Levels then dropped progress-
ively up to day 120 (4months), weremaintained up to
day 180 (6 months) and became non-detectable bey-
ond 6 months. However, in our case, IV administra-
tion of 0.1 mg of DEX in the form of a suspension
(10 mg ml−1) of DEX/LAP (1:10 w w−1), in addition
to presenting the advantage of being administered as
a mild nanogel injected by 25 G needle [74], pro-
duced a short and early peak release of DEX at day
1 (2258.00 ± 1610.32 ng g−1) followed by a drop
at week 1 and a subsequent plateau DEX vitreous
level for up to 6 months (466.32 ± 311.15 ng g−1),
even though the dose of DEX administered was
lower than that of Ozurdex® (0.1 vs 0.7 mg). IV
DEX/LAP decreased the time and minimized other
ocular structures’ exposure to high levels of DEX (at
week 1) and, therefore, reduced the risk of devel-
oping cataracts, ocular hypertension or corticoster-
oid glaucoma. In our study, no animal developed
these potential long-term complications following IV
administration of DEX/LAP. In this regard, studies
conducted with IV Illuvien® implants, with more
posterior placement than Retisert®, decreased OHT
events when compared with the latter. The fact that
the DEX/LAP formulation is not an implantable
insert and can be placed away from the ciliary body
and iridocorneal angle may have helped to maintain
ocular normotension.
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The initial peak in DEX levels in the vitreous
humour (matching that observed in in vitro studies
[61]) may be due to the release of DEX from the
surface of the LAP, with the entrapped DEX sub-
sequently being released sustainedly [62]. Our find-
ings showed that the use of LAP as a carrier exten-
ded the half-life of the DEX in the vitreous when
compared with IV injection of the DEX in solu-
tion (134.75 vs 0.13 d). The LAP increased the vis-
cosity of the formulation, which increased its resid-
ence time and bioavailability [26, 75]. In addition,
highly cationic molecules such as LAP may find their
mobility limited and so aggregate in the vitreous. In
our study, we observed the DEX/LAP formulation as
a single semi-transparent aggregate in the vitreous
throughout the study.
However, the goal of IV administration is to
achieve DEX levels in the choroid-retina unit, where
the drug exerts its greatest effect. IV administration
of 0.7 mg of Ozurdex® produces a peak in retinal
DEX at day 60 (Cmax 1110 ng g−1) followed by a steep
decline up to week 12 (0.0167 ng g−1 at day 210)
and no detectable level after day 240.66. In our study,
unfortunately, following IV administration of 0.1 mg
of DEX in the form of a suspension (10 mg ml−1)
of DEX/LAP (1:10 w/w), DEX levels were below the
detection limit.
4.2. Analysis of SC administration
SC administration presents several advantages over
IV administration, among them lower risk of haem-
orrhage in the pars plana, not creating opacity in the
visual axis (cataracts or floating bodies), better tar-
geting of the choroid-retina unit and lower immune
response. This higher potential is manifested in the
number of SC administration patents registered, as
well as in the growing number of publications in
recent years in which this route is used [36].
Administration of 0.05 mg of DEX—in the
form of a suspension (10 mg ml−1) of DEX/LAP
(1:10 w w−1)—in the SCS produced (despite of the
non-quantified leaking at injection time) a peak in
DEX in the choroid-retina unit at week 1 (Cmax
275.54 ± 164.85 ng g−1) followed by a progressive
decline up to week 12 and plateauing up to week 24
(Cmax 12.04 ± 20.85 ng g−1). SC administration of
DEX/LAP increased DEX availability in the choroid-
retina compared with IV injection of Ozurdex® (AUC
9786 vs 47 200 ng g−1 d−1) and was also maintained
more consistently and prolongedly until the end of
the study [70, 73]. This could prevent overdosing,
fluctuations and side effects, as no animal in the study
showed increases in IOP, cataracts or infection after
SC administration of DEX/LAP. The presence of DEX
levels in the choroid-retina unit at the end of the study
can be explained by retention of the formulation as
a macro-aggregate at the injection site (SCS), act-
ing as a reservoir from where DEX is slowly released
over time. The pore size of the choriocapillaris ves-
sels is estimated at 6 nm, meaning that during biode-
gradation of the gel small subcomponents of it could
pass through the pores and thus produce progress-
ive release. In this regard, Chiang et al [27] showed
how non-rigid molecules (DEX or even DEX/LAP
nano-aggregates in our case) can adapt and pass
through the fenestrations (whichwould coincidewith
the initial burst). Polystyrene particles of between
20 nm and 10 µm, however, were still retained in the
SCS 2 months after injection [76]. In our study, the
DEX/LAP aggregate was retained in the SCS for up to
6 months, enabling prolonged release of the drug.
Olsen et al [29] asserted that the sustained release
of small molecules may indicate an ideal candidate
for SC administration, as they clear quickly by them-
selves (2 d) [27]. The distribution of small molecules
in the posterior segment, after SC administration,
was studied using fluorescein as a model. As DEX
has a slightly lower molecular mass than fluorescein
(332 vs 392.46 Daltons), we consider the latter’s beha-
viour to be extrapolatable to the GC in our study.
Small molecules spread rapidly throughout the pos-
terior segment [22], meaning that the DEX released
in the initial burst could be widely distributed. Pre-
vious studies show an approximate asymmetrical cir-
cumferential distribution of 50%, which is limited in
the equatorial area by the vascular barriers of the long
posterior ciliary arteries (LPCAs) in rabbits or the
short ones in humans [27, 51]. In our study, the SC
injection site selected was 9 mm from the limbus in
order to avoid possible ectasia, due to the increased
scleral thinning in the pre-equatorial region [41], and
to overcome the LCPA barriers and so achieve wider
potential distribution of our formulation in the pos-
terior segment.
In contrast, agents with LAP-like viscous and
hydrophilic properties, such as carboxymethylcellu-
lose (CMC), expand and increase their area at the
SC injection site for up to 2 d after administration
[27]. In addition, the use of hydrogels has shown
an increase in particle distribution secondary to an
osmotic push [33], although it is generally located at
the injection site, since the more viscous a formula-
tion is the less it is distributed [51]. Low-viscosity for-
mulations expand with a constant thickness. How-
ever, if the viscosity of the formulation is increased,
the thickness of the SCS likewise increases [27] (to
more than 30microns under normal conditions) [22]
until reaching a maximum thickness after gelatine
injection of 250 microns [77], at which point the
viscosity matches the biomechanical resistance exer-
ted by the tissues. This makes it possible to place
the formulation at a specific site away from the cil-
iary body so as to prevent ocular hypertension or to
treat specific sites/targets. The nanogel DEX/LAP for-
mulation remained at the injection site and could
be observed and delimited macroscopically at the
moment of injection (figure 4). Thus, although in
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our study we do not evaluate the placement or dis-
tribution of the DEX/LAP formulation, based on his-
tological studies or imaging tests using fluorescent
markers or stains the above evidence suggests that
DEX/LAP may behave in a similar way.
The LAP swells in an aqueous medium and facil-
itates −OH−H + exchange of the drug (in our case,
DEX). This may be what caused higher and earlier
levels (initial burst) of DEX to be detected in the
most hydrated tissues. Our study showed that the
highest concentration of DEX, following SC admin-
istration of DEX/LAP, was detected in the vitreous
humour, followed by the sclera. Chiang et al [27]
found that after initial leaking, the main clearance
route for small molecules was transscleral diffusion.
The sclera shows increased permeability to small
molecules (such as DEX) and decreased permeability
to macromolecules (LAP aggregate), thus retaining
them. As the LAP was not cleared by the transscleral
route, the DEX could be released sustainedly to the
choroid-retina unit (12.04 ± 20.85 ng g−1) and
sclera (25.46 ± 44.09 ng g−1) (greater in the sclera
as it is a more hydrated tissue) through to the end of
the study.
The DEX’s hydrophilia was also considered
responsible for the greater early loss rate in the tis-
sues with the greatest water component: the vitreous,
followed by the choroid-retina unit (even when the
formulation is injected directly there), the sclera and
the crystalline cone. The high concentration of DEX
in the vitreous after SC injection was noteworthy
because the RPE-choroid has thin bonds that, under
normal conditions, restrict the passage of hydrosol-
uble or polar molecules, such as DEX, to the retina.
Thus, these unexpectedly high concentrations in the
vitreous suggest a possible disruption of the Bruch
membrane in the rabbits in this study. In this regard,
disruption of the RPE may occur with application
of certain injection and/or cannulation techniques
in the SCS, as we used in this study [10]. The use
of standardized microneedles (as Clearside®) for SC
administration seems important, as gauge, length and
injection force, as well as type of formulation, influ-
ence placement of the formulation in the SCS. And
probably, the use of these standardized microneedles
would avoid the undesirable initial leaking. Viscous
gels may require long needles or extended injection
times, although there are cases in which gel-type for-
mulations have been injected using 30 G needles and
the LAP’s thixotropic property would facilitate this
[78]. Using microneedles 1 mm long appears to be
advisable so as to avoid puncturing the choroidal
vasculature [52].
Most studies of SC administration of GCs have
been conducted with TA due to its intrinsic sustained
release capability. Animal and human studies showed
an increase in TA levels in the choroid-retina unit
and sclera up to 6 months after administration, with
levels decreasing in anterior structures and less need
for re-injection when compared with IV administra-
tion [23, 40, 42].
To our knowledge, there has only been one study
of administering DEX in the SCS [53]. This study
demonstrated the safety and efficacy of controlling
inflammation in rats with uveitis following the sur-
gical placement of a slow-degradation polyurethane/-
DEX implant with a semi-crystalline structure. How-
ever, it did not analyse in vivo pharmacokinetics. The
in vitro release study shows that the DEX release pro-
file of the implant exhibited a higher initial burst than
that observed with our DEX/LAP formulation (55%
vs 40%), as was the case in our study in week 1, as
well as subsequent sustained release of shorter dura-
tion (42 d vs 6 months) [61]. However, it uses much
higher doses of DEX (6, 18.8 and 29 mg) than used in
our DEX/LAP SC delivery study (0.05 mg of DEX in
the form of a suspension (10 mg ml−1) of DEX/LAP
(1:10 w w−1)) [53].
4.3. Comparison between IV and SC route for
DEX/LAP formulation
Both routes of administration were safe and the com-
bination with LAP allowed sustained and longer ocu-
lar levels of DEX compared to a conventional injec-
tion. Our results suggest a greater benefit of the
SC route of DEX/LAP compared to the IV route.
Although the SC route led to increased hyperemia and
epithelial defects, these inconveniences were attrib-
uted to the surgical intervention of the cannulation
process. It could be minimized with the use of injec-
tions such as Clearside®. The SC route produced
reversible and time-limited side effects on the ocu-
lar surface. However, iatrogenesis by IV injection was
permanent (cataract) and generated a vision of floater
with potential visual alteration until the end of the
study. It did not occur with the SC route.
The SC route maintained sustained levels of DEX
in ocular tissues with a lower amount of drug injec-
ted into the eye (0.1 IV vs. 0.05 mg SC). The IV route
exhibited higher dilution and greater initial burst.
Therefore, tomaintain prolonged eye levels it is neces-
sary to administer a greater amount of DEX, which
carries a potential greater risk of side effects such as
cataracts or ocular hypertension (although no animal
developed these complications).
Nowadays, it would be convenient to carry out
further studies on SC administration to facilitate the
wide use of this route in daily practice. The extens-
ive experience obtained with IV injections in clinical
practice makes the IV route also have to be con-
sidered. The authors recommend evaluating the suit-
ability of using one route or another depending on the
individual characteristics of each patient. IV adminis-
tration could bemore suitable to treat pathologies (1)
of inner neuroretina, or 2) with intraocular inflam-
mation of the posterior pole, (3) requiring wider dif-
fusion of the drug, (4) with necessity of an attack
dose and subsequent control of immunity, (5) and in
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Figure 4. Placement of the DEX/LAP formulation in the SC space.
which visual quality is not the first handicap to solve
at that stage. However, the SC route seems ideal to
treat pathologies (1) of outer retina (2) that require
a targeted location and (3) in need of preserving the
available visual quality of the patient at that time.
4.4. Limitations and objectives for future studies
The analytical medium used in this study to quantify
the DEX was only able to detect DEX levels in the vit-
reous, not in the other tissues analysed, so unfortu-
nately comparison of DEX in retina-choroid between
the two administration routes could not be made.
No blood tests were performed to determine DEX
levels, (further studies for quantification of plasma
DEX concentration would be interesting to further
validate the ocular PK data) nor were histological
studies conducted to confirm the correct placement
of the DEX/LAP formulation in the SCS, its distribu-
tion area, its degradation over time and its effect on
the near tissue.
The PK behaviour of a substance can be modi-
fied by the presence of disease, which causes tissue-
specific bonds to form faster. Future studies using
models of inflammatory ocular disease will allow
for better understanding of the pharmacodynamics
and comparison with those of other formulations or
devices. Development of formulations that modu-
late the release of DEX from the LAP carrier based
on pH or temperature is also considered of interest,
as in the presence of disease the medium becomes
more acidotic and its temperature rises due to the
increase in flow and cell activity. In these situations,
there could potentially be greater degradation of the
DEX/LAP formulation and, therefore, greater release
of DEX, positioning it as a shock treatment. Sub-
sequently, with the improvement in the hyperkinetic
pathology, the degradation of the DEX/LAP would
decrease while maintaining low-level sustained DEX
release, allowing a form of control or maintenance.
5. Conclusions
The DEX/LAP formulation was administered by
minimally invasive IV injection and by safe SC
administration in healthy rabbits. A single IV or SC
administration of the DEX/LAP formulation pro-
duced the progressive release of DEX and exten-
ded the residence time in the vitreous humour and
choroid-retina unit by up to 6 months when com-
pared with conventional formulations. DEX/LAP
could therefore be considered as a biocompatible
sustained-release formulation to treat ocular pos-
terior segment diseases.
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